Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Medicine combination and application thereof in preparing preparations for treating chronic hepatitis B

A technology for chronic hepatitis B and its composition, which is applied in the field of preparation of preparations for treating chronic hepatitis B, can solve the problems of repeated disease, drug resistance, HBV mutation, etc., and achieve the effect of regulating immune function and enhancing immunity

Active Publication Date: 2010-01-20
JIUZHITANG
View PDF0 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although lamivudine has a good curative effect in the treatment of chronic hepatitis B, long-term use of patients will produce HBV mutations, and the longer the course of treatment, the higher the incidence of mutations, resulting in drug resistance and recurrence of the disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine combination and application thereof in preparing preparations for treating chronic hepatitis B
  • Medicine combination and application thereof in preparing preparations for treating chronic hepatitis B
  • Medicine combination and application thereof in preparing preparations for treating chronic hepatitis B

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] The BCG polysaccharide nucleic acid required by the present invention can be obtained by the following methods, but those skilled in the art can understand that the preparation of BCG polysaccharide nucleic acid includes but is not limited to this method:

[0020] 1) Cultivation and harvest of BCG

[0021] 1. Bacterial cell culture: dissolve the liquid cryopreserved strain (BCG strain D2PB302 for the preparation of BCG vaccine in China, China Institute for the Control of Pharmaceutical and Biological Products) at room temperature, inoculate it in potato Sutong medium, and continuously cultivate at 37°C for 14-20 days ; Or cultivated continuously at 37℃ for 15 days and then transferred to modified liquid Sutong medium, and cultivated continuously at 37℃ for 14-20 days.

[0022] 2. Bacteria collection: When the bacteria grow to the logarithmic phase, check the culture flask bottle by bottle, collect the bacterial membrane, add an appropriate amount of deionized distilled water t...

Embodiment 2

[0039] The method for producing powder injection of pharmaceutical composition with BCG polysaccharide nucleic acid as the active ingredient, the prescription is:

[0040] BCG nucleic acid: 0.3g

[0041] Physiological sodium chloride solution (0.9%): 100ml

[0042] Take a prescription amount of ordinary lyophilized powder D BCG polysaccharide nucleic acid and an appropriate amount of water for injection and mix evenly. Those skilled in the art can also understand that the BCG polysaccharide nucleic acid can be in the form of micropowder, solid dispersion, inclusion compound, microsphere, Add in the form of liposomes or microparticles. After fully dissolving, centrifuge at 4000 rpm and 3°C for 15 minutes. Take the supernatant and test the content of polysaccharide and nucleic acid. After the test is qualified, the supernatant passes 0.22 The μm filter is finely filtered, and the filtrate is autoclaved and steam-sterilized and then packed into vials, freeze-dried, stoppered, and cappe...

Embodiment 3

[0044] The preparation method of the pharmaceutical composition injection with BCG polysaccharide nucleic acid as the active ingredient, the prescription is:

[0045] BCG nucleic acid: 0.3g

[0046] Physiological sodium chloride solution (0.9%) or water for injection: 100ml

[0047] Take the prescription amount of BCG polysaccharide nucleic acid and appropriate amount of physiological sodium chloride solution (0.9%) or water for injection, mix well, dissolve it thoroughly, centrifuge at 4000 rpm, 3°C for 15 minutes, take the supernatant, and proceed The content of polysaccharide and nucleic acid is tested. After the test is qualified, the supernatant is filtered through a 0.22μm filter, and then filled in an ampoule, and autoclaved steam sterilization can be injected into a pharmaceutical composition with BCG polysaccharide nucleic acid as the active ingredient liquid. Give the patient an intramuscular injection of 1 ml every other day.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a medicine combination and the application thereof in preparing preparations for treating chronic hepatitis B. The combination comprises a medicine combination with polysaccharide nucleic acid of bacillus calmette guerin as the active component and a Chinese traditional medicine combination, wherein the Chinese traditional medicine combination is prepared from astragalus, herba artemisiae scopariae, oldenlandia diffusa, herba lysimachiae, codonopsis pilosula, processed polygonum capitatum, salvia, radix paeoniae alba, chinaberry fruit, taraxacum, cortex moutan, poria and atractylodes; the polysaccharide nucleic acid of bacillus calmette Guerin is nonspecific immunity active reinforcer, and can effectively restrain the reproduction of hepatitis virus and promote the rapid negative turning of HBV-DNA and HbeAg; and the Chinese traditional medicine combination has the efficacy of invigorating qi and spleen, promoting blood circulation by removing blood stasis and clearing away heat and toxic material. The medicine combination can reduce the incidence rate of variation and drug resistance and effectively promote the improvement under the condition of improving the healing efficacy, and provides a novel, safe and effective drug choice for clinics.

Description

Technical field [0001] The invention relates to a pharmaceutical composition and its application in preparing a preparation for treating chronic hepatitis B. Background technique [0002] Chronic hepatitis B (HBV) infection is a global health problem. It is estimated that about 350 million people worldwide are infected with hepatitis B virus, 75% of whom live in the Asia-Pacific region. In my country, about 120 million people are carriers of hepatitis B virus. 28 million, the prevalence rate is as high as 2770 / 100,000, of which one-third of hepatitis B patients will develop into chronic hepatitis, cirrhosis or liver cancer. In 1998, about 2 million people worldwide died of viral-induced liver cancer. The death toll in my country was 300,000. The World Health Organization has listed hepatitis B as the ninth leading cause of death in the world. Moreover, once people are infected with hepatitis virus, they must take medicine for a long time. The annual treatment cost for various vir...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K36/74A61P37/02A61P31/20A61P1/16A61K35/74
Inventor 宁云山关继峰张燚
Owner JIUZHITANG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products